0.00Open9.34Pre Close0 Volume30 Open Interest15.00Strike Price0.00Turnover512.02%IV41.97%PremiumJan 17, 2025Expiry Date2.15Intrinsic Value100Multiplier10DDays to Expiry7.20Extrinsic Value100Contract SizeAmericanOptions Type0.7304Delta0.0221Gamma2.50Leverage Ratio-0.2544Theta0.0017Rho1.83Eff Leverage0.0096Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet